nodes	percent_of_prediction	percent_of_DWPC	metapath
Dihydroergotamine—ABCB1—Mitoxantrone—lymphatic system cancer	0.0896	0.206	CbGbCtD
Dihydroergotamine—CYP3A4—Cytarabine—lymphatic system cancer	0.0779	0.18	CbGbCtD
Dihydroergotamine—CYP3A4—Teniposide—lymphatic system cancer	0.0768	0.177	CbGbCtD
Dihydroergotamine—ABCB1—Vincristine—lymphatic system cancer	0.0617	0.142	CbGbCtD
Dihydroergotamine—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0537	0.124	CbGbCtD
Dihydroergotamine—ABCB1—Methotrexate—lymphatic system cancer	0.0373	0.086	CbGbCtD
Dihydroergotamine—CYP3A4—Vincristine—lymphatic system cancer	0.0369	0.0851	CbGbCtD
Dihydroergotamine—Chills—Fludarabine—lymphatic system cancer	0.00277	0.0049	CcSEcCtD
Dihydroergotamine—Face oedema—Carmustine—lymphatic system cancer	0.00276	0.00487	CcSEcCtD
Dihydroergotamine—Hypertension—Teniposide—lymphatic system cancer	0.00264	0.00467	CcSEcCtD
Dihydroergotamine—Muscular weakness—Carmustine—lymphatic system cancer	0.00252	0.00445	CcSEcCtD
Dihydroergotamine—Confusional state—Teniposide—lymphatic system cancer	0.00252	0.00445	CcSEcCtD
Dihydroergotamine—Oedema—Teniposide—lymphatic system cancer	0.0025	0.00441	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.0025	0.00441	CcSEcCtD
Dihydroergotamine—Ill-defined disorder—Fludarabine—lymphatic system cancer	0.0025	0.00441	CcSEcCtD
Dihydroergotamine—Acute coronary syndrome—Bleomycin—lymphatic system cancer	0.00249	0.00439	CcSEcCtD
Dihydroergotamine—Myocardial infarction—Bleomycin—lymphatic system cancer	0.00247	0.00437	CcSEcCtD
Dihydroergotamine—Agitation—Fludarabine—lymphatic system cancer	0.00247	0.00437	CcSEcCtD
Dihydroergotamine—Dysphagia—Carmustine—lymphatic system cancer	0.00247	0.00436	CcSEcCtD
Dihydroergotamine—Stupor—Methotrexate—lymphatic system cancer	0.00244	0.00431	CcSEcCtD
Dihydroergotamine—Tachycardia—Teniposide—lymphatic system cancer	0.00244	0.00431	CcSEcCtD
Dihydroergotamine—Malaise—Fludarabine—lymphatic system cancer	0.00243	0.00428	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Teniposide—lymphatic system cancer	0.00241	0.00426	CcSEcCtD
Dihydroergotamine—Muscular weakness—Vincristine—lymphatic system cancer	0.00241	0.00425	CcSEcCtD
Dihydroergotamine—Pruritus—Mechlorethamine—lymphatic system cancer	0.0024	0.00423	CcSEcCtD
Dihydroergotamine—Anorexia—Teniposide—lymphatic system cancer	0.00238	0.00421	CcSEcCtD
Dihydroergotamine—Hypotension—Teniposide—lymphatic system cancer	0.00233	0.00412	CcSEcCtD
Dihydroergotamine—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00232	0.00409	CcSEcCtD
Dihydroergotamine—Myalgia—Fludarabine—lymphatic system cancer	0.00229	0.00404	CcSEcCtD
Dihydroergotamine—Arthralgia—Fludarabine—lymphatic system cancer	0.00229	0.00404	CcSEcCtD
Dihydroergotamine—Discomfort—Fludarabine—lymphatic system cancer	0.00226	0.004	CcSEcCtD
Dihydroergotamine—Hypoaesthesia—Bleomycin—lymphatic system cancer	0.00225	0.00398	CcSEcCtD
Dihydroergotamine—Sweating increased—Mitoxantrone—lymphatic system cancer	0.00224	0.00395	CcSEcCtD
Dihydroergotamine—Dyspnoea—Teniposide—lymphatic system cancer	0.00223	0.00393	CcSEcCtD
Dihydroergotamine—Petechiae—Methotrexate—lymphatic system cancer	0.00222	0.00392	CcSEcCtD
Dihydroergotamine—Confusional state—Fludarabine—lymphatic system cancer	0.00221	0.00391	CcSEcCtD
Dihydroergotamine—Oedema—Fludarabine—lymphatic system cancer	0.00219	0.00388	CcSEcCtD
Dihydroergotamine—Decreased appetite—Teniposide—lymphatic system cancer	0.00217	0.00383	CcSEcCtD
Dihydroergotamine—Vomiting—Mechlorethamine—lymphatic system cancer	0.00215	0.0038	CcSEcCtD
Dihydroergotamine—Rash—Mechlorethamine—lymphatic system cancer	0.00214	0.00377	CcSEcCtD
Dihydroergotamine—Upper respiratory tract infection—Mitoxantrone—lymphatic system cancer	0.00213	0.00377	CcSEcCtD
Dihydroergotamine—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00213	0.00377	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.00212	0.00375	CcSEcCtD
Dihydroergotamine—Speech disorder—Methotrexate—lymphatic system cancer	0.00212	0.00375	CcSEcCtD
Dihydroergotamine—Flushing—Bleomycin—lymphatic system cancer	0.0021	0.00371	CcSEcCtD
Dihydroergotamine—Anorexia—Fludarabine—lymphatic system cancer	0.00209	0.0037	CcSEcCtD
Dihydroergotamine—Acute coronary syndrome—Vincristine—lymphatic system cancer	0.00207	0.00366	CcSEcCtD
Dihydroergotamine—Myocardial infarction—Vincristine—lymphatic system cancer	0.00206	0.00364	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Teniposide—lymphatic system cancer	0.00206	0.00364	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00204	0.00361	CcSEcCtD
Dihydroergotamine—Musculoskeletal stiffness—Methotrexate—lymphatic system cancer	0.00203	0.00359	CcSEcCtD
Dihydroergotamine—Chills—Bleomycin—lymphatic system cancer	0.00203	0.00359	CcSEcCtD
Dihydroergotamine—Acute coronary syndrome—Mitoxantrone—lymphatic system cancer	0.00202	0.00357	CcSEcCtD
Dihydroergotamine—Nausea—Mechlorethamine—lymphatic system cancer	0.00201	0.00355	CcSEcCtD
Dihydroergotamine—Myocardial infarction—Mitoxantrone—lymphatic system cancer	0.00201	0.00355	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.002	0.00353	CcSEcCtD
Dihydroergotamine—Conjunctivitis—Mitoxantrone—lymphatic system cancer	0.00199	0.00352	CcSEcCtD
Dihydroergotamine—Urticaria—Teniposide—lymphatic system cancer	0.00198	0.0035	CcSEcCtD
Dihydroergotamine—Herpes simplex—Methotrexate—lymphatic system cancer	0.00198	0.0035	CcSEcCtD
Dihydroergotamine—Body temperature increased—Teniposide—lymphatic system cancer	0.00197	0.00349	CcSEcCtD
Dihydroergotamine—Abdominal pain—Teniposide—lymphatic system cancer	0.00197	0.00349	CcSEcCtD
Dihydroergotamine—Paraesthesia—Fludarabine—lymphatic system cancer	0.00197	0.00348	CcSEcCtD
Dihydroergotamine—Hypoaesthesia—Carmustine—lymphatic system cancer	0.00197	0.00348	CcSEcCtD
Dihydroergotamine—Dyspnoea—Fludarabine—lymphatic system cancer	0.00196	0.00346	CcSEcCtD
Dihydroergotamine—Dyspepsia—Fludarabine—lymphatic system cancer	0.00193	0.00341	CcSEcCtD
Dihydroergotamine—Sinusitis—Mitoxantrone—lymphatic system cancer	0.00192	0.00339	CcSEcCtD
Dihydroergotamine—Decreased appetite—Fludarabine—lymphatic system cancer	0.00191	0.00337	CcSEcCtD
Dihydroergotamine—Visual impairment—Carmustine—lymphatic system cancer	0.00191	0.00337	CcSEcCtD
Dihydroergotamine—Fatigue—Fludarabine—lymphatic system cancer	0.00189	0.00334	CcSEcCtD
Dihydroergotamine—Hypoaesthesia—Vincristine—lymphatic system cancer	0.00188	0.00332	CcSEcCtD
Dihydroergotamine—Pain—Fludarabine—lymphatic system cancer	0.00188	0.00332	CcSEcCtD
Dihydroergotamine—Rhinitis—Mitoxantrone—lymphatic system cancer	0.00184	0.00326	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Teniposide—lymphatic system cancer	0.00184	0.00325	CcSEcCtD
Dihydroergotamine—Flushing—Carmustine—lymphatic system cancer	0.00183	0.00324	CcSEcCtD
Dihydroergotamine—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.00183	0.00323	CcSEcCtD
Dihydroergotamine—Pharyngitis—Mitoxantrone—lymphatic system cancer	0.00182	0.00322	CcSEcCtD
Dihydroergotamine—Vaginal inflammation—Methotrexate—lymphatic system cancer	0.00182	0.00322	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00181	0.00319	CcSEcCtD
Dihydroergotamine—Asthenia—Teniposide—lymphatic system cancer	0.00179	0.00317	CcSEcCtD
Dihydroergotamine—Cystitis noninfective—Methotrexate—lymphatic system cancer	0.00178	0.00315	CcSEcCtD
Dihydroergotamine—Malaise—Bleomycin—lymphatic system cancer	0.00178	0.00314	CcSEcCtD
Dihydroergotamine—Pruritus—Teniposide—lymphatic system cancer	0.00177	0.00312	CcSEcCtD
Dihydroergotamine—Depressed level of consciousness—Methotrexate—lymphatic system cancer	0.00176	0.00311	CcSEcCtD
Dihydroergotamine—Cystitis—Methotrexate—lymphatic system cancer	0.00176	0.00311	CcSEcCtD
Dihydroergotamine—Body temperature increased—Fludarabine—lymphatic system cancer	0.00173	0.00306	CcSEcCtD
Dihydroergotamine—Vaginal infection—Methotrexate—lymphatic system cancer	0.00172	0.00304	CcSEcCtD
Dihydroergotamine—Diarrhoea—Teniposide—lymphatic system cancer	0.00171	0.00302	CcSEcCtD
Dihydroergotamine—Myalgia—Bleomycin—lymphatic system cancer	0.00168	0.00297	CcSEcCtD
Dihydroergotamine—Discomfort—Bleomycin—lymphatic system cancer	0.00166	0.00293	CcSEcCtD
Dihydroergotamine—Chills—Mitoxantrone—lymphatic system cancer	0.00165	0.00291	CcSEcCtD
Dihydroergotamine—Bladder pain—Methotrexate—lymphatic system cancer	0.00165	0.00291	CcSEcCtD
Dihydroergotamine—Confusional state—Bleomycin—lymphatic system cancer	0.00162	0.00287	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00162	0.00286	CcSEcCtD
Dihydroergotamine—Tremor—Carmustine—lymphatic system cancer	0.00161	0.00285	CcSEcCtD
Dihydroergotamine—Oedema—Bleomycin—lymphatic system cancer	0.00161	0.00284	CcSEcCtD
Dihydroergotamine—Vomiting—Teniposide—lymphatic system cancer	0.00159	0.0028	CcSEcCtD
Dihydroergotamine—Agitation—Carmustine—lymphatic system cancer	0.00158	0.00279	CcSEcCtD
Dihydroergotamine—Asthenia—Fludarabine—lymphatic system cancer	0.00157	0.00278	CcSEcCtD
Dihydroergotamine—Rash—Teniposide—lymphatic system cancer	0.00157	0.00278	CcSEcCtD
Dihydroergotamine—Dermatitis—Teniposide—lymphatic system cancer	0.00157	0.00278	CcSEcCtD
Dihydroergotamine—Headache—Teniposide—lymphatic system cancer	0.00156	0.00276	CcSEcCtD
Dihydroergotamine—Pruritus—Fludarabine—lymphatic system cancer	0.00155	0.00274	CcSEcCtD
Dihydroergotamine—Anorexia—Bleomycin—lymphatic system cancer	0.00153	0.00271	CcSEcCtD
Dihydroergotamine—Agitation—Vincristine—lymphatic system cancer	0.00151	0.00267	CcSEcCtD
Dihydroergotamine—Hypotension—Bleomycin—lymphatic system cancer	0.0015	0.00266	CcSEcCtD
Dihydroergotamine—Diarrhoea—Fludarabine—lymphatic system cancer	0.0015	0.00265	CcSEcCtD
Dihydroergotamine—Hypertension—Carmustine—lymphatic system cancer	0.00149	0.00262	CcSEcCtD
Dihydroergotamine—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.00148	0.00262	CcSEcCtD
Dihydroergotamine—Nausea—Teniposide—lymphatic system cancer	0.00148	0.00262	CcSEcCtD
Dihydroergotamine—Vertigo—Vincristine—lymphatic system cancer	0.00148	0.00261	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00147	0.00259	CcSEcCtD
Dihydroergotamine—Myalgia—Carmustine—lymphatic system cancer	0.00147	0.00259	CcSEcCtD
Dihydroergotamine—Anxiety—Carmustine—lymphatic system cancer	0.00146	0.00258	CcSEcCtD
Dihydroergotamine—Paraesthesia—Bleomycin—lymphatic system cancer	0.00144	0.00255	CcSEcCtD
Dihydroergotamine—Malaise—Mitoxantrone—lymphatic system cancer	0.00144	0.00255	CcSEcCtD
Dihydroergotamine—Dyspnoea—Bleomycin—lymphatic system cancer	0.00143	0.00253	CcSEcCtD
Dihydroergotamine—Hypertension—Vincristine—lymphatic system cancer	0.00142	0.00251	CcSEcCtD
Dihydroergotamine—Confusional state—Carmustine—lymphatic system cancer	0.00142	0.0025	CcSEcCtD
Dihydroergotamine—Oedema—Carmustine—lymphatic system cancer	0.0014	0.00248	CcSEcCtD
Dihydroergotamine—Decreased appetite—Bleomycin—lymphatic system cancer	0.0014	0.00247	CcSEcCtD
Dihydroergotamine—Myalgia—Vincristine—lymphatic system cancer	0.0014	0.00247	CcSEcCtD
Dihydroergotamine—Vomiting—Fludarabine—lymphatic system cancer	0.0014	0.00247	CcSEcCtD
Dihydroergotamine—Rash—Fludarabine—lymphatic system cancer	0.00138	0.00244	CcSEcCtD
Dihydroergotamine—Dermatitis—Fludarabine—lymphatic system cancer	0.00138	0.00244	CcSEcCtD
Dihydroergotamine—Hypertension—Mitoxantrone—lymphatic system cancer	0.00138	0.00244	CcSEcCtD
Dihydroergotamine—Pain—Bleomycin—lymphatic system cancer	0.00138	0.00243	CcSEcCtD
Dihydroergotamine—Headache—Fludarabine—lymphatic system cancer	0.00137	0.00243	CcSEcCtD
Dihydroergotamine—Tachycardia—Carmustine—lymphatic system cancer	0.00137	0.00242	CcSEcCtD
Dihydroergotamine—Arthralgia—Mitoxantrone—lymphatic system cancer	0.00136	0.00241	CcSEcCtD
Dihydroergotamine—Myalgia—Mitoxantrone—lymphatic system cancer	0.00136	0.00241	CcSEcCtD
Dihydroergotamine—Anxiety—Mitoxantrone—lymphatic system cancer	0.00136	0.0024	CcSEcCtD
Dihydroergotamine—Cerebrovascular accident—Methotrexate—lymphatic system cancer	0.00135	0.00239	CcSEcCtD
Dihydroergotamine—Discomfort—Mitoxantrone—lymphatic system cancer	0.00135	0.00238	CcSEcCtD
Dihydroergotamine—Oedema—Vincristine—lymphatic system cancer	0.00134	0.00237	CcSEcCtD
Dihydroergotamine—Anorexia—Carmustine—lymphatic system cancer	0.00134	0.00237	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00133	0.00234	CcSEcCtD
Dihydroergotamine—Confusional state—Mitoxantrone—lymphatic system cancer	0.00132	0.00233	CcSEcCtD
Dihydroergotamine—Hypotension—Carmustine—lymphatic system cancer	0.00131	0.00232	CcSEcCtD
Dihydroergotamine—Oedema—Mitoxantrone—lymphatic system cancer	0.00131	0.00231	CcSEcCtD
Dihydroergotamine—Nausea—Fludarabine—lymphatic system cancer	0.0013	0.0023	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Vincristine—lymphatic system cancer	0.0013	0.00229	CcSEcCtD
Dihydroergotamine—Shock—Mitoxantrone—lymphatic system cancer	0.00128	0.00227	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00128	0.00226	CcSEcCtD
Dihydroergotamine—Urticaria—Bleomycin—lymphatic system cancer	0.00128	0.00226	CcSEcCtD
Dihydroergotamine—Anorexia—Vincristine—lymphatic system cancer	0.00128	0.00226	CcSEcCtD
Dihydroergotamine—Tachycardia—Mitoxantrone—lymphatic system cancer	0.00127	0.00225	CcSEcCtD
Dihydroergotamine—Body temperature increased—Bleomycin—lymphatic system cancer	0.00127	0.00225	CcSEcCtD
Dihydroergotamine—Insomnia—Carmustine—lymphatic system cancer	0.00127	0.00224	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00126	0.00223	CcSEcCtD
Dihydroergotamine—Paraesthesia—Carmustine—lymphatic system cancer	0.00126	0.00223	CcSEcCtD
Dihydroergotamine—Hypotension—Vincristine—lymphatic system cancer	0.00125	0.00221	CcSEcCtD
Dihydroergotamine—Dyspnoea—Carmustine—lymphatic system cancer	0.00125	0.00221	CcSEcCtD
Dihydroergotamine—Somnolence—Carmustine—lymphatic system cancer	0.00125	0.00221	CcSEcCtD
Dihydroergotamine—Anorexia—Mitoxantrone—lymphatic system cancer	0.00124	0.0022	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00122	0.00216	CcSEcCtD
Dihydroergotamine—Decreased appetite—Carmustine—lymphatic system cancer	0.00122	0.00216	CcSEcCtD
Dihydroergotamine—Hypotension—Mitoxantrone—lymphatic system cancer	0.00122	0.00216	CcSEcCtD
Dihydroergotamine—Insomnia—Vincristine—lymphatic system cancer	0.00121	0.00214	CcSEcCtD
Dihydroergotamine—Paraesthesia—Vincristine—lymphatic system cancer	0.0012	0.00213	CcSEcCtD
Dihydroergotamine—Pain—Carmustine—lymphatic system cancer	0.0012	0.00212	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00119	0.0021	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00119	0.00209	CcSEcCtD
Dihydroergotamine—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.00117	0.00207	CcSEcCtD
Dihydroergotamine—Decreased appetite—Vincristine—lymphatic system cancer	0.00117	0.00206	CcSEcCtD
Dihydroergotamine—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00116	0.00206	CcSEcCtD
Dihydroergotamine—Somnolence—Mitoxantrone—lymphatic system cancer	0.00116	0.00205	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Carmustine—lymphatic system cancer	0.00116	0.00204	CcSEcCtD
Dihydroergotamine—Fatigue—Vincristine—lymphatic system cancer	0.00116	0.00204	CcSEcCtD
Dihydroergotamine—Asthenia—Bleomycin—lymphatic system cancer	0.00115	0.00204	CcSEcCtD
Dihydroergotamine—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00115	0.00203	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00115	0.00203	CcSEcCtD
Dihydroergotamine—Pain—Vincristine—lymphatic system cancer	0.00115	0.00203	CcSEcCtD
Dihydroergotamine—Pruritus—Bleomycin—lymphatic system cancer	0.00114	0.00201	CcSEcCtD
Dihydroergotamine—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.00114	0.00201	CcSEcCtD
Dihydroergotamine—Fatigue—Mitoxantrone—lymphatic system cancer	0.00113	0.00199	CcSEcCtD
Dihydroergotamine—Pain—Mitoxantrone—lymphatic system cancer	0.00112	0.00197	CcSEcCtD
Dihydroergotamine—Body temperature increased—Carmustine—lymphatic system cancer	0.00111	0.00196	CcSEcCtD
Dihydroergotamine—Abdominal pain—Carmustine—lymphatic system cancer	0.00111	0.00196	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.0011	0.00194	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00108	0.0019	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.00107	0.00189	CcSEcCtD
Dihydroergotamine—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.00106	0.00188	CcSEcCtD
Dihydroergotamine—Abdominal pain—Vincristine—lymphatic system cancer	0.00106	0.00187	CcSEcCtD
Dihydroergotamine—Body temperature increased—Vincristine—lymphatic system cancer	0.00106	0.00187	CcSEcCtD
Dihydroergotamine—Urticaria—Mitoxantrone—lymphatic system cancer	0.00104	0.00183	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Carmustine—lymphatic system cancer	0.00103	0.00183	CcSEcCtD
Dihydroergotamine—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.00103	0.00182	CcSEcCtD
Dihydroergotamine—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.00103	0.00182	CcSEcCtD
Dihydroergotamine—Vomiting—Bleomycin—lymphatic system cancer	0.00102	0.00181	CcSEcCtD
Dihydroergotamine—Rash—Bleomycin—lymphatic system cancer	0.00101	0.00179	CcSEcCtD
Dihydroergotamine—Dermatitis—Bleomycin—lymphatic system cancer	0.00101	0.00179	CcSEcCtD
Dihydroergotamine—Asthenia—Carmustine—lymphatic system cancer	0.00101	0.00178	CcSEcCtD
Dihydroergotamine—Conjunctivitis—Methotrexate—lymphatic system cancer	0.000992	0.00175	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Vincristine—lymphatic system cancer	0.000988	0.00175	CcSEcCtD
Dihydroergotamine—Epistaxis—Methotrexate—lymphatic system cancer	0.000962	0.0017	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000962	0.0017	CcSEcCtD
Dihydroergotamine—Asthenia—Vincristine—lymphatic system cancer	0.000962	0.0017	CcSEcCtD
Dihydroergotamine—Diarrhoea—Carmustine—lymphatic system cancer	0.000961	0.0017	CcSEcCtD
Dihydroergotamine—Nausea—Bleomycin—lymphatic system cancer	0.000956	0.00169	CcSEcCtD
Dihydroergotamine—Asthenia—Mitoxantrone—lymphatic system cancer	0.000937	0.00166	CcSEcCtD
Dihydroergotamine—Dizziness—Carmustine—lymphatic system cancer	0.000929	0.00164	CcSEcCtD
Dihydroergotamine—Diarrhoea—Vincristine—lymphatic system cancer	0.000917	0.00162	CcSEcCtD
Dihydroergotamine—Pharyngitis—Methotrexate—lymphatic system cancer	0.000909	0.00161	CcSEcCtD
Dihydroergotamine—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000893	0.00158	CcSEcCtD
Dihydroergotamine—Vomiting—Carmustine—lymphatic system cancer	0.000893	0.00158	CcSEcCtD
Dihydroergotamine—Dizziness—Vincristine—lymphatic system cancer	0.000887	0.00157	CcSEcCtD
Dihydroergotamine—Rash—Carmustine—lymphatic system cancer	0.000886	0.00156	CcSEcCtD
Dihydroergotamine—Dermatitis—Carmustine—lymphatic system cancer	0.000885	0.00156	CcSEcCtD
Dihydroergotamine—Visual impairment—Methotrexate—lymphatic system cancer	0.000882	0.00156	CcSEcCtD
Dihydroergotamine—Headache—Carmustine—lymphatic system cancer	0.00088	0.00155	CcSEcCtD
Dihydroergotamine—Tinnitus—Methotrexate—lymphatic system cancer	0.000854	0.00151	CcSEcCtD
Dihydroergotamine—Vomiting—Vincristine—lymphatic system cancer	0.000853	0.00151	CcSEcCtD
Dihydroergotamine—Rash—Vincristine—lymphatic system cancer	0.000845	0.00149	CcSEcCtD
Dihydroergotamine—Dermatitis—Vincristine—lymphatic system cancer	0.000845	0.00149	CcSEcCtD
Dihydroergotamine—Headache—Vincristine—lymphatic system cancer	0.00084	0.00148	CcSEcCtD
Dihydroergotamine—Nausea—Carmustine—lymphatic system cancer	0.000834	0.00147	CcSEcCtD
Dihydroergotamine—Vomiting—Mitoxantrone—lymphatic system cancer	0.00083	0.00147	CcSEcCtD
Dihydroergotamine—Rash—Mitoxantrone—lymphatic system cancer	0.000823	0.00145	CcSEcCtD
Dihydroergotamine—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000823	0.00145	CcSEcCtD
Dihydroergotamine—Chills—Methotrexate—lymphatic system cancer	0.000822	0.00145	CcSEcCtD
Dihydroergotamine—Headache—Mitoxantrone—lymphatic system cancer	0.000818	0.00145	CcSEcCtD
Dihydroergotamine—Nausea—Vincristine—lymphatic system cancer	0.000796	0.00141	CcSEcCtD
Dihydroergotamine—Nausea—Mitoxantrone—lymphatic system cancer	0.000776	0.00137	CcSEcCtD
Dihydroergotamine—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.00074	0.00131	CcSEcCtD
Dihydroergotamine—Malaise—Methotrexate—lymphatic system cancer	0.000719	0.00127	CcSEcCtD
Dihydroergotamine—Vertigo—Methotrexate—lymphatic system cancer	0.000716	0.00127	CcSEcCtD
Dihydroergotamine—Arthralgia—Methotrexate—lymphatic system cancer	0.000679	0.0012	CcSEcCtD
Dihydroergotamine—Myalgia—Methotrexate—lymphatic system cancer	0.000679	0.0012	CcSEcCtD
Dihydroergotamine—Discomfort—Methotrexate—lymphatic system cancer	0.000671	0.00118	CcSEcCtD
Dihydroergotamine—Confusional state—Methotrexate—lymphatic system cancer	0.000656	0.00116	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000629	0.00111	CcSEcCtD
Dihydroergotamine—Anorexia—Methotrexate—lymphatic system cancer	0.00062	0.0011	CcSEcCtD
Dihydroergotamine—Hypotension—Methotrexate—lymphatic system cancer	0.000608	0.00107	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000593	0.00105	CcSEcCtD
Dihydroergotamine—Insomnia—Methotrexate—lymphatic system cancer	0.000588	0.00104	CcSEcCtD
Dihydroergotamine—Paraesthesia—Methotrexate—lymphatic system cancer	0.000584	0.00103	CcSEcCtD
Dihydroergotamine—Dyspnoea—Methotrexate—lymphatic system cancer	0.00058	0.00102	CcSEcCtD
Dihydroergotamine—Somnolence—Methotrexate—lymphatic system cancer	0.000578	0.00102	CcSEcCtD
Dihydroergotamine—Dyspepsia—Methotrexate—lymphatic system cancer	0.000573	0.00101	CcSEcCtD
Dihydroergotamine—Decreased appetite—Methotrexate—lymphatic system cancer	0.000566	0.000999	CcSEcCtD
Dihydroergotamine—Fatigue—Methotrexate—lymphatic system cancer	0.000561	0.000991	CcSEcCtD
Dihydroergotamine—Pain—Methotrexate—lymphatic system cancer	0.000556	0.000983	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000536	0.000947	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000532	0.00094	CcSEcCtD
Dihydroergotamine—Urticaria—Methotrexate—lymphatic system cancer	0.000517	0.000913	CcSEcCtD
Dihydroergotamine—Abdominal pain—Methotrexate—lymphatic system cancer	0.000514	0.000909	CcSEcCtD
Dihydroergotamine—Body temperature increased—Methotrexate—lymphatic system cancer	0.000514	0.000909	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000479	0.000847	CcSEcCtD
Dihydroergotamine—Asthenia—Methotrexate—lymphatic system cancer	0.000467	0.000825	CcSEcCtD
Dihydroergotamine—Pruritus—Methotrexate—lymphatic system cancer	0.00046	0.000813	CcSEcCtD
Dihydroergotamine—Diarrhoea—Methotrexate—lymphatic system cancer	0.000445	0.000786	CcSEcCtD
Dihydroergotamine—Dizziness—Methotrexate—lymphatic system cancer	0.00043	0.00076	CcSEcCtD
Dihydroergotamine—Vomiting—Methotrexate—lymphatic system cancer	0.000414	0.000731	CcSEcCtD
Dihydroergotamine—Rash—Methotrexate—lymphatic system cancer	0.00041	0.000725	CcSEcCtD
Dihydroergotamine—Dermatitis—Methotrexate—lymphatic system cancer	0.00041	0.000724	CcSEcCtD
Dihydroergotamine—Headache—Methotrexate—lymphatic system cancer	0.000408	0.00072	CcSEcCtD
Dihydroergotamine—Nausea—Methotrexate—lymphatic system cancer	0.000386	0.000683	CcSEcCtD
